Targeted Immuno-Oncology Gene Therapy
Multiple Cancers
Pre-clinicalActive
Key Facts
About Scopus BioPharma
Scopus BioPharma is a private, pre-revenue biotech leveraging strategic academic partnerships to advance a pipeline of RNA and gene therapies. The company's core strategy involves in-licensing and co-developing ground-breaking discoveries from premier institutions like City of Hope, the NIH, and Hebrew University. Its most advanced asset is a targeted immuno-oncology gene therapy for cancer, positioning it in the competitive but high-potential field of next-generation oncology treatments. Leadership combines financial expertise from healthcare-focused investment firm HCFP with scientific guidance from an experienced advisory board.
View full company profileTherapeutic Areas
Other Multiple Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| CAML/CTC Assay for MRD & Recurrence | Creatv Bio | Clinical Research |
| Therapy Monitoring & Companion Diagnostic Services | Creatv Bio | Service Offering |
| Biopharma MRD-Guided Trial Services | Natera | Collaborative Development |
| GT90001 | Kintor Pharma | Phase 2 |